ClinicalTrials.govpublic full text
Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis
deep vein thrombosis, cancer, residual vein thrombosis, low molecular weight heparin, optimal duration, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 861987
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.